Year All20252024202320222021202020192018201720162015201420122011 Feb 27, 2023 Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference Feb 23, 2023 Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023 Feb 2, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Dec 29, 2022 FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) Dec 23, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Dec 16, 2022 Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 22, 2022 Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference Nov 16, 2022 Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 16, 2022 Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 4, 2022 National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels